Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Geisen, U; Brehm, K; Trummer, G; Berchtold-Herz, M; Heilmann, C; Beyersdorf, F; Schelling, J; Schlagenhauf, A; Zieger, B.
Platelet Secretion Defects and Acquired von Willebrand Syndrome in Patients With Ventricular Assist Devices.
J Am Heart Assoc. 2018; 7(2): [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Schlagenhauf Axel
Altmetrics:

Dimensions Citations:

Plum Analytics:
Number of Figures: 6
| | | | | |
Abstract:
The number of implanted ventricular assist devices (VADs) has increased significantly recently. Bleeding, the most frequent complication, cannot be solely attributed to anticoagulation therapy. Acquired von Willebrand syndrome (AVWS) caused by increased shear stress is frequent in VAD patients and can increase the bleeding risk. The HeartMate III (HM III) is a novel left VAD featuring potential improvements over the HeartMate II. In this study, we investigated the prevalence and onset of AVWS in 198 VAD patients. To our knowledge, this is the largest cohort of VAD patients whose longitudinal data on AVWS have been collected. We also analyzed whether AVWS is less severe in HM III patients than in HeartMate II patients. Because platelet dysfunction can raise the bleeding risk, we investigated platelet function in a subset of patients. In total, 198 VAD patients and 60 patients with heart transplants as controls were included in this study. The ratio of von Willebrand factor collagen binding capacity to von Willebrand factor:antigen, multimer analyses, and platelet function (especially secretion of α- and δ-granules) were investigated. All 198 VAD patients developed AVWS. As soon as the VAD was explanted, the AVWS disappeared within hours. AVWS was less severe in the HM III patients than in the HeartMate II patients. The HM III patients had fewer bleeding symptoms. In addition, VAD patients exhibited a platelet α- and δ-granule secretion defect. AVWS develops in VAD patients and may increase the bleeding risk. The HM III device causes less severe AVWS. Platelet secretion defects should be investigated in VAD patients because they also raise the bleeding risk. https://www.drks.de/drks_web. Unique identifier: DRKS00000649. © 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

Find related publications in this database (Keywords)
platelet
ventricular assist device
von Willebrand factor
© Meduni Graz Impressum